Transcriptional Activation by the Product of Open Reading Frame 50 of Kaposi’s Sarcoma-Associated Herpesvirus Is Required for Lytic Viral Reactivation in B Cells

ABSTRACT Kaposi’s sarcoma (KS)-associated herpesvirus (KSHV) is a lymphotropic virus strongly linked to the development of KS, an endothelial cell neoplasm frequent in persons with AIDS. Reactivation from latency in B cells is thought to be an important antecedent to viral spread to endothelial cells during KS pathogenesis. Earlier experiments have posited a role for the transcriptional activator encoded by KSHV open reading frame 50 (ORF50) in such reactivation, since ectopic overexpression of this protein induces reactivation in latently infected B cells. Here we have explored several aspects of the expression, structure, and function of this protein bearing on this role. The ORF50 gene is expressed very early in lytic reactivation, before several other genes implicated as candidate regulatory genes in related viruses, and its expression can upregulate their promoters in transient assays. The protein is extensively phosphorylated in vivo and bears numerous sites for phosphorylation by protein kinase C, activators of which are potent stimulators of lytic induction. The C terminus of the ORF50 protein contains a domain that can strongly activate transcription when targeted to DNA; deletion of this domain generates an allele that expresses a truncated protein which retains the ability to form multimers with full-length ORF50 and functions as a dominant-negative protein. Expression of this allele in latently infected cells ablates spontaneous reactivation from latency and strikingly suppresses viral replication induced by multiple stimuli, including phorbol ester, ionomycin, and sodium butyrate. These results indicate that the ORF50 gene product plays an essential role in KSHV lytic replication and are consistent with its action as a putative molecular switch controlling the induction of virus from latency.

[1]  Lijun Wu,et al.  A Complex Translational Program Generates Multiple Novel Proteins from the Latently Expressed Kaposin (K12) Locus of Kaposi’s Sarcoma-Associated Herpesvirus , 1999, Journal of Virology.

[2]  A. Haase,et al.  Expression of the Open Reading Frame 74 (G-Protein-Coupled Receptor) Gene of Kaposi’s Sarcoma (KS)-Associated Herpesvirus: Implications for KS Pathogenesis , 1999, Journal of Virology.

[3]  F. Zhu,et al.  Identification of the Immediate-Early Transcripts of Kaposi’s Sarcoma-Associated Herpesvirus , 1999, Journal of Virology.

[4]  A. Palestine,et al.  Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. , 1999, The New England journal of medicine.

[5]  R. Sun,et al.  Kinetics of Kaposi’s Sarcoma-Associated Herpesvirus Gene Expression , 1999, Journal of Virology.

[6]  H. Kung,et al.  Kaposi’s Sarcoma-Associated Herpesvirus Encodes a bZIP Protein with Homology to BZLF1 of Epstein-Barr Virus , 1999, Journal of Virology.

[7]  H. Gruffat,et al.  Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) encodes a homologue of the Epstein-Barr virus bZip protein EB1. , 1999, The Journal of general virology.

[8]  R. Desrosiers,et al.  Identification and Characterization of Kaposi’s Sarcoma-Associated Herpesvirus K8.1 Virion Glycoprotein , 1999, Journal of Virology.

[9]  D. Ganem,et al.  Reactivation of Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R protein. , 1998, Virology.

[10]  W. Kolch,et al.  Activation of the Epstein-Barr Virus Transcription Factor BZLF1 by 12-O-Tetradecanoylphorbol-13-Acetate-Induced Phosphorylation , 1998, Journal of Virology.

[11]  T. Ragoczy,et al.  The Epstein-Barr Virus Rta Protein Activates Lytic Cycle Genes and Can Disrupt Latency in B Lymphocytes , 1998, Journal of Virology.

[12]  R. Sun,et al.  A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[13]  T. Schulz,et al.  Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8). , 1998, The Journal of general virology.

[14]  R. Ricciardi,et al.  Cloning and Functional Analysis of Kaposi’s Sarcoma-Associated Herpesvirus DNA Polymerase and Its Processivity Factor , 1998, Journal of Virology.

[15]  Jeffrey N. Martin,et al.  Sexual transmission and the natural history of human herpesvirus 8 infection. , 1998, The New England journal of medicine.

[16]  F. Neipel,et al.  The immunogenic glycoprotein gp35-37 of human herpesvirus 8 is encoded by open reading frame K8.1. , 1998, Journal of virology.

[17]  P. Moore,et al.  Transcription Mapping of the Kaposi’s Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Genome in a Body Cavity-Based Lymphoma Cell Line (BC-1) , 1998, Journal of Virology.

[18]  B. Chandran,et al.  Identification and characterization of human herpesvirus-8 lytic cycle-associated ORF 59 protein and the encoding cDNA by monoclonal antibody. , 1998, Virology.

[19]  E. Cesarman,et al.  G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator , 1998, Nature.

[20]  C. Boshoff,et al.  Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. , 1997, Science.

[21]  B. Haar,et al.  Monocytes in Kaposi's sarcoma lesions are productively infected by human herpesvirus 8 , 1997, Journal of virology.

[22]  F. Neipel,et al.  Cell-homologous genes in the Kaposi's sarcoma-associated rhadinovirus human herpesvirus 8: determinants of its pathogenicity? , 1997, Journal of virology.

[23]  E. Cesarman,et al.  Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation , 1997, Nature.

[24]  A. Haase,et al.  Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells , 1997, Journal of virology.

[25]  J. Russo,et al.  Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[26]  S. Kenney,et al.  Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27]  W. Zhong,et al.  Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. McGrath,et al.  Lytic growth of Kaposi's sarcoma–associated herpesvirus (human herpesvirus 8) in culture , 1996, Nature Medicine.

[29]  L. Corbo,et al.  Epstein-Barr virus (EBV) EB1/Zta protein provided in trans and competent for the activation of productive cycle genes does not activate the BZLF1 gene in the EBV genome. , 1996, The Journal of general virology.

[30]  J. Countryman,et al.  Comparing transcriptional activation and autostimulation by ZEBRA and ZEBRA/c-Fos chimeras , 1996, Journal of virology.

[31]  D R Hoover,et al.  Kaposi's sarcoma-associated herpesvirus infection prior to onset of Kaposi's sarcoma , 1996, AIDS.

[32]  C. Boshoff,et al.  Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells , 1995, Nature Medicine.

[33]  C. Boshoff,et al.  Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma , 1995, The Lancet.

[34]  F. Sigaux,et al.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. , 1995, Blood.

[35]  E. Cesarman,et al.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. , 1995, The New England journal of medicine.

[36]  J. Ambroziak,et al.  Herpes-like sequences in HIV-infected and uninfected Kaposi's sarcoma patients. , 1995, Science.

[37]  J. Levy,et al.  Characterization of a human Kaposi's sarcoma cell line that induces angiogenic tumors in animals , 1994, AIDS.

[38]  H. Gruffat,et al.  Characterization of the DNA-binding site repertoire for the Epstein-Barr virus transcription factor R. , 1994, Nucleic acids research.

[39]  F. Furnari,et al.  RAZ, an Epstein-Barr virus transdominant repressor that modulates the viral reactivation mechanism , 1994, Journal of virology.

[40]  A. Berk,et al.  Functional interaction of adenovirus E1A with holo-TFIID. , 1993, Genes & development.

[41]  D. Gutsch,et al.  Direct BRLF1 binding is required for cooperative BZLF1/BRLF1 activation of the Epstein-Barr virus early promoter, BMRF1. , 1993, Nucleic acids research.

[42]  E. Fearon,et al.  Karyoplasmic interaction selection strategy: a general strategy to detect protein-protein interactions in mammalian cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[43]  M. Stürzl,et al.  Cellular and molecular features of HIV-associated Kaposi's sarcoma. , 1992, AIDS.

[44]  J M Hardwick,et al.  The Epstein-Barr virus R transactivator (Rta) contains a complex, potent activation domain with properties different from those of VP16 , 1992, Journal of virology.

[45]  R. Buckland,et al.  Characterization of an R-binding site mediating the R-induced activation of the Epstein-Barr virus BMLF1 promoter , 1992, Journal of virology.

[46]  J. Giot,et al.  Domains of the Epstein-Barr virus (EBV) transcription factor R required for dimerization, DNA binding and activation. , 1991, Nucleic acids research.

[47]  P. Farrell,et al.  Pathways of activation of the Epstein-Barr virus productive cycle , 1991, Journal of virology.

[48]  W. D. Cress,et al.  Critical structural elements of the VP16 transcriptional activation domain. , 1991, Science.

[49]  S. Kenney,et al.  The Epstein-Barr virus (EBV) BMRF1 promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner , 1990, Journal of virology.

[50]  G. Miller The switch between latency and replication of Epstein-Barr virus. , 1990, The Journal of infectious diseases.

[51]  E. Flemington,et al.  Autoregulation of Epstein-Barr virus putative lytic switch gene BZLF1 , 1990, Journal of virology.

[52]  J. Hardwick,et al.  An enhancer within the divergent promoter of Epstein-Barr virus responds synergistically to the R and Z transactivators , 1990, Journal of virology.

[53]  K. Takada,et al.  Identification of an enhancer-type sequence that is responsive to Z and R trans-activators of Epstein-Barr virus. , 1989, Virology.

[54]  S. Kenney,et al.  The Epstein-Barr virus BMLF1 promoter contains an enhancer element that is responsive to the BZLF1 and BRLF1 transactivators , 1989, Journal of virology.

[55]  I. Verma,et al.  Modification of fos proteins: phosphorylation of c-fos, but not v-fos, is stimulated by 12-tetradecanoyl-phorbol-13-acetate and serum , 1987, Molecular and cellular biology.

[56]  P. Chavrier,et al.  Both Epstein‐Barr virus (EBV)‐encoded trans‐acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter. , 1986, The EMBO journal.

[57]  J. Countryman,et al.  Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. , 1985, Proceedings of the National Academy of Sciences of the United States of America.